Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster session 14

333P - Efficacy and cell-free DNA whole methylome based biomarker analysis of carboplatin plus taxanes neoadjuvant chemotherapy in triple negative breast cancer: A prospective multi-center cohort study

Date

14 Sep 2024

Session

Poster session 14

Topics

Cytotoxic Therapy;  Translational Research

Tumour Site

Breast Cancer

Presenters

Xi Chen

Citation

Annals of Oncology (2024) 35 (suppl_2): S349-S356. 10.1016/annonc/annonc1578

Authors

X. Chen1, M. Xiu2, H. Kang3, Y. Zhang4, Q. Li2, X. Cheng5, J. Wang6, B. Lan7, S. Chen2, M. Xiao1, X. Qian2, B. Hua8, B. Xu1, P. Zhang9

Author affiliations

  • 1 Medical Oncology, Chinese Academy of Medical Sciences and Peking Union Medical College - National Cancer Center, Cancer Hospital, 100021 - Beijing/CN
  • 2 Department Of Medical Oncology, Chinese Academy of Medical Sciences and Peking Union Medical College - National Cancer Center, Cancer Hospital, 100021 - Beijing/CN
  • 3 Center For Thyroid And Breast Surgery, Department Of General Surgery,, Beijing Xuan Wu Hospital, 100053 - Beijing/CN
  • 4 Center For Thyroid And Breast Surgery, Department Of General Surgery,, Xuanwu Hospital Capital Medical University, 100053 - Beijing/CN
  • 5 Genecast Biotechnology, Genecast Biotechnology Co., Ltd., 100191 - Beijing/CN
  • 6 Department Of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College,, 100021 - beijing/CN
  • 7 Medical Oncology Dept., Chinese Academy of Medical Sciences and Peking Union Medical College - National Cancer Center, Cancer Hospital, 100021 - Beijing/CN
  • 8 Department Of Medical Oncology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, 100730 - Beijing/CN
  • 9 Oncology Department, Cancer Hospital Chinese Academy of Medical Sciences, 100122 - Beijing/CN

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 333P

Background

The efficacy and survival data of carboplatin plus taxane neoadjuvant chemotherapy(NAC) in triple-negative breast cancer(TNBC) was lack of a large-sample study. The predictive biomarker of efficacy based on cell-free DNA (cfDNA) whole-methylome sequencing (WMS) has not been reported yet.

Methods

The prospective multi-center cohort study was conducted in four hospitals of China between 2016 and 2023. Stage II-III TNBC patients were enrolled to receive NAC of carboplatin (AUC 5) every 3 weeks or carboplatin (AUC 4) every 2 weeks plus taxane(standard dose) for 4-6 cycles. Plasma samples were prospectively collected at baseline(T1) and after NAC (T2). Chromosomal aneuploidy of featured fragments (CAFF), fragment size index (FSI) and methylation density score (MD) of cfDNA were detected with WMS.

Results

A total of 267 patients were included in the study. The median age was 49 years, 156 patients (58.4%) were stage III disease. 147 patients (55.1%) received the triweekly NAC. 263 patients underwent breast surgery after NAC and 106 patients (40.3%) achieved pCR. The pCR were similar in biweekly or triweekly groups (39.8% vs 40.7%, P=0.89). The 3-year RFS and overall survival (OS) were 77.9%, 87.6%, respectively. Patients who achieved pCR had a significant better RFS (95.5%) and OS (97.7%) than those non-pCR (76.6%, P<0.001; 81.2%, P<0.001). A total of 66 patients with 120 plasma samples (64 samples at T1, 56 samples at T2) were included in WMS analysis. Patients with CAFF, FSI or MD positive at T1 had a higher tumor burden (stage III or cN2-3, all P values <0.05). The proportion of patients with FSI negative at T2 was significantly higher in pCR group compared to non-pCR (86.2% vs 59.3%, P=0.034). There is a similar tendency in patients with CAFF negative. Patients with MD positive at T1 was significantly associated with poor RFS compared to MD negative (HR = 7.36, 95% CI: 0.93-58.75, Log-rank P=0.028).

Conclusions

Our large-sample study further confirmed that carboplatin plus taxanes NAC in TNBC is an effective regimen choice. Biomarkers based on cfDNA WMS may offer some predictive and prognostic value which needed to be further investigated.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.